2'-DEOXY-L-CYTIDINE manufacturers
- 2'-DEOXY-L-CYTIDINE
-
- $5.00 / 5KG
-
2019-08-05
- CAS:40093-94-5
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1ton
Related articles - Uses and toxicity of Torcitabine
- Torcitabine (b-L-2u-deoxycytidine) (L-dC) is the b-L-enantiomer of the natural nucleoside D-cytidine. The drug is currently un....
- Apr 8，2022
|
| | 2'-DEOXY-L-CYTIDINE Basic information |
| Product Name: | 2'-DEOXY-L-CYTIDINE | | Synonyms: | BETA-L-2'-DEOXYCYTIDINE;4-AMino-1-((2R,4R,5S)-4-hydroxy-5-(hydroxyMethyl)tetrahydrofuran-2-yl)pyriMidin-2(1H)-one;L-2'-deoxycytidine;2'-DEOXY-L-CYTIDINE;4-amino-1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one;2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-b-L-erythro-pentofuranosyl)-;2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-β-L-erythro-pentofuranosyl)-;Torcitabine | | CAS: | 40093-94-5 | | MF: | C9H13N3O4 | | MW: | 227.22 | | EINECS: | 500-100-4 | | Product Categories: | | | Mol File: | 40093-94-5.mol |  |
| | 2'-DEOXY-L-CYTIDINE Chemical Properties |
| Boiling point | 497.6±55.0 °C(Predicted) | | density | 1.73±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 250 mg/mL (1100.26 mM) | | pka | 14.03±0.60(Predicted) | | Water Solubility | Water: 250 mg/mL (1100.26 mM) |
| | 2'-DEOXY-L-CYTIDINE Usage And Synthesis |
| Description | Torcitabine (b-L-2u-deoxycytidine) (L-dC) is the b-L-enantiomer of the natural nucleoside D-cytidine. The drug is currently under development by Idenix as an antiviral agent for the treatment of chronic hepatitis B virus infection. Torcitabine has poor oral bioavailability, but its 3u,5u-divaline ester (val-L-dC) and the 3u-monovaline ester, valtorcitabine dihydrochloride, have excellent oral bioavailability and consequently the torcitabine prodrug, valtorcitabine, has replaced torcitabine in clinical development. | | Uses | Torcitabine and its prodrug, valtorcitabine, are investigational drugs being developed solely for the treatment of chronic HBV infection. Torcitabine itself has undergone preliminary phase I/II clinical trials in HBeAg-positive patients, initially as the 3u,5u-divalyl prodrug in escalating doses of 50, 100, 200, and 400 mg/day, but later as the more stable monovaline ester form, valtorcitabine dihydrochloride, and administered to four cohorts in doses of 300, 600, 900, and 1200 mg/ day for 28 days. |
| | 2'-DEOXY-L-CYTIDINE Preparation Products And Raw materials |
|